Atul Dandekar - 27 Feb 2026 Form 4 Insider Report for Maze Therapeutics, Inc. (MAZE)

Reporting relationship: CSBO
Issuer ticker: MAZE
Reported as of: 27 Feb 2026
Net transaction value: -$262,573
SEC form: 4
Accepted by SEC: 03 Mar 2026, 16:25:41 UTC
Prior SEC filing: 02 Feb 2026
Next SEC filing: 01 Apr 2026
Source filing: View source filing
Reporting owner signature: /s/ Courtney Phillips, as attorney-in-fact

Key filing fact

Atul Dandekar filed Form 4 for Maze Therapeutics, Inc. (MAZE) on 03 Mar 2026.

Key facts

This page summarizes Atul Dandekar's Form 4 filing for Maze Therapeutics, Inc. (MAZE).
6 reported transactions and 3 derivative rows are listed below.
Accepted by SEC: 03 Mar 2026, 16:25.

Change

Previous filing in this sequence was filed on 02 Feb 2026.
Current net transaction value: -$262,573.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0002050167 Primary reporting owner

Dandekar Atul

Relationship: CSBO
Address: C/O MAZE THERAPEUTICS, INC., 171 OYSTER POINT BOULEVARD, SUITE 300, SOUTH SAN FRANCISCO
Signature: /s/ Courtney Phillips, as attorney-in-fact
Signature date: 03 Mar 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

MAZE transaction

Common Stock

Options Exercise

Transaction value: $78,150
Shares: +7,500
Change %: +71%
Price: $10.42
Shares after: 18,003
Date: 27 Feb 2026
Ownership: Direct
Footnotes: F1

MAZE transaction

Common Stock

Sale

Transaction value: $168,756
Shares: -3,739
Change %: -21%
Price: $45.13
Shares after: 14,264
Date: 27 Feb 2026
Ownership: Direct
Footnotes: F1, F2

MAZE transaction

Common Stock

Sale

Transaction value: $171,967
Shares: -3,761
Change %: -26%
Price: $45.72
Shares after: 10,503
Date: 27 Feb 2026
Ownership: Direct
Footnotes: F1, F3

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

MAZE transaction Derivative

Stock Option (Right to Buy)

Options Exercise

Transaction value: $0
Shares: -7,500
Change %: -11%
Price: $0.000000
Shares after: 59,143
Date: 27 Feb 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 7,500
Exercise price: $10.42
Footnotes: F1, F4

MAZE transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +38,000
Change %
Price: $0.000000
Shares after: 38,000
Date: 02 Mar 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 38,000
Exercise price: $45.61
Footnotes: F5

MAZE transaction Derivative

Restricted Stock Units

Award

Transaction value: $0
Shares: +19,000
Change %
Price: $0.000000
Shares after: 19,000
Date: 02 Mar 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 19,000
Exercise price
Footnotes: F6, F7, F8

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 8 footnotes

Footnote F1

This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2025.

Footnote F2

The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $44.55 to $45.54 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and in footnote 3 of this Form 4.

Footnote F3

The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $45.55 to $46.02 per share, inclusive.

Footnote F4

The option is fully vested. Pursuant to the terms of the reporting person's award agreement with the Issuer, the award became fully vested on March 17, 2025.

Footnote F5

The option award shall vest as to 1/48 of the total award monthly, with the first tranche vesting on April 1, 2026, subject to the reporting person's continued service to the Issuer on each vesting date.

Footnote F6

Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock upon settlement.

Footnote F7

The restricted stock unit award shall vest in ratable increments of 1/4 of the total award, with the first tranche vesting on March 1, 2027, and vesting thereafter on the one year anniversary of such date, subject to the reporting person's continued service to the Issuer on each vesting date.

Footnote F8

These restricted stock units do not expire; they either vest or are cancelled prior to the vesting date.